Innovent’s Xinbimin IGF‑1R Antibody Approved in Macau
CompanyDrug

Innovent’s Xinbimin IGF‑1R Antibody Approved in Macau

TransThera Begins Phase II Tinengotinib Trial with Akeso Bispecifics for Advanced HCC
CompanyDrug

TransThera Begins Phase II Tinengotinib Trial with Akeso Bispecifics for Advanced HCC

Simcere Launches Quviviq, New Insomnia Therapy in China
CompanyDrug

Simcere Launches Quviviq, New Insomnia Therapy in China

Hengrui Licenses HRS‑1893 to Braveheart Bio in $75 M Deal – Global Myosin Inhibitor
CompanyDeals

Hengrui Licenses HRS‑1893 to Braveheart Bio in $75 M Deal – Global Myosin Inhibitor

Dongcheng Pharma to Spin‑Off Lannacheng for HK Main Board Listing – Radiopharma Focus
CompanyDeals

Dongcheng Pharma to Spin‑Off Lannacheng for HK Main Board Listing – Radiopharma Focus

Hengrui’s SHR‑A2009 ADC Gains NMPA Approval for HER3‑Targeted Tumor Therapy
CompanyDrug

Hengrui’s SHR‑A2009 ADC Gains NMPA Approval for HER3‑Targeted Tumor Therapy

Haisco Pharmaceutical’s HSK47388 Gears Up for New Autoimmune Trial – NMPA Approval
CompanyDrug

Haisco Pharmaceutical’s HSK47388 Gears Up for New Autoimmune Trial – NMPA Approval

Boji Medical’s FCZR Approved for Otomycosis Trials – First Liquid Eardrop in China
CompanyDrug

Boji Medical’s FCZR Approved for Otomycosis Trials – First Liquid Eardrop in China

Hengrui’s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase 3
CompanyDrug

Hengrui’s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase 3

Biocytogen, Merck Partner on Antibody‑Conjugated Lipid Nanoparticles
CompanyDeals

Biocytogen, Merck Partner on Antibody‑Conjugated Lipid Nanoparticles

Argo Biopharma, Novartis Expand siRNA Collaboration for Cardiovascular Drugs
CompanyDeals

Argo Biopharma, Novartis Expand siRNA Collaboration for Cardiovascular Drugs

ChemPartner & Toposcend Form $200 M Healthcare Fund to Back Innovative Drugs
CompanyDeals

ChemPartner & Toposcend Form $200 M Healthcare Fund to Back Innovative Drugs